New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new ...

BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an all-stock deal valued at around $1.25 billion.